News & Videos - HERON THERAPEUTICS INC. - Page 2

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain PR Newswire SAN DIEGO, Jan. 7, 2024 SAN DIEGO , Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network...

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance PR Newswire SAN DIEGO, Nov. 14, 2023 Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million and full-year 2024 Net Product Sales to be in the range of $138 million to $158...

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 PR Newswire SAN DIEGO, Nov. 7, 2023 SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30...

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates PR Newswire SAN DIEGO, Aug. 14, 2023 Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise Favorable outcome at Markman hearing in pending CINVANTI ® ANDA patent litigation New management team in place Reiterating full-year net product sales guidance for the oncology care franchise of $99 - $103 million SAN DIEGO , Aug. 14, 2023...

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 PR Newswire SAN DIEGO, Aug. 7, 2023 SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Monday, August 14, 2023 at 4:30 p.m....

Heron Therapeutics Announces Cost Reduction Plan and Restructuring PR Newswire SAN DIEGO, July 24, 2023 - Expected overall cash savings of $75 million through 2025 - New executive management team in place SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a cost reduction plan and a...

Heron Therapeutics Announces $30 Million Private Placement Financing PR Newswire SAN DIEGO, July 24, 2023 SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purchase agreement to sell in a private placement to institutional investors, led by...

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer PR Newswire SAN DIEGO, June 23, 2023 SAN DIEGO , June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years...

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer PR Newswire SAN DIEGO, June 12, 2023 SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes , Pharm.D., as Executive Vice President, Chief...

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire SAN DIEGO, May 11, 2023 · Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million , Compared to First Quarter Net Product Sales in 2022 · Appointment of Craig Collard as Chief Executive Officer (CEO) and Jason Grillot as Vice President (VP), Sales and Marketing, of the Acute Care Franchise. SAN DIEGO , May 11, 2023 /PRNewswire/ -- Heron...

Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 PR Newswire SAN DIEGO, May 4, 2023 SAN DIEGO , May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, May 11, 2023 at...

Heron Therapeutics Announces Commercial Leadership Changes PR Newswire SAN DIEGO, April 20, 2023 SAN DIEGO , April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and...

Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO, April 17, 2023 SAN DIEGO , April 17, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Craig Collard , Chief Executive Officer of Heron, will participate in a fireside...

Heron Therapeutics Announces New CEO and Board Chairman PR Newswire SAN DIEGO, April 3, 2023 Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO , April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX ) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief...

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates PR Newswire SAN DIEGO, March 23, 2023 - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE ™ Commercially Launched on March 6, 2023 - - ZYNRELEF ® Net Product Sales for Fourth Quarter of 2022 Increased 44% Over Prior Quarter to $3.9 Million - - Oncology Care Franchise...

Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023 PR Newswire SAN DIEGO, March 13, 2023 SAN DIEGO , March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved...

Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023 PR Newswire SAN DIEGO, March 10, 2023 SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on...

Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults PR Newswire SAN DIEGO, March 6, 2023 - APONVIE, the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK 1 ) receptor antagonist indicated for Postoperative Nausea and Vomiting (PONV) - - APONVIE is d elivered via a single IV push and offers 48 hours of PONV prevention - - Leveraging existing acute care commercial teams across the U.S. - SAN...

Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference PR Newswire SAN DIEGO, Feb. 27, 2023 SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat on Tuesday, March 7, 2023 at 2:10 PM...

Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital PR Newswire SAN DIEGO, Feb. 22, 2023 Appoints Three New Independent Directors SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a...